Hydrogenology
Hydrogenology editorial study record

Improvement of psoriasis-associated arthritis and skin lesions by treatment with molecular hydrogen: a report of three cases

Ishibashi T, Ichikawa M, Sato B, Shibata S, Hara Y, Naritomi Y, Okazaki K, Nakashima Y, Iwamoto Y, Koyanagi S, Hara H, Nagao T. · Mol Med Rep. 2015;12(2):2757–2764.

HumanInhaled H₂Published 2015
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Case series with alternating H₂ modalities

Research topic

Skin, wound and aging research

Administration classification

Inhaled H₂

Study result signal

Exploratory case observations; indeterminate efficacy.

Outcome type

Clinical scores and inflammatory biomarkers in three selected cases.

Reported in the source

Methods at a glance

Population or model

Three people with psoriasis and/or psoriatic arthritis.

Sample

3 cases.

Duration

Five-day modality periods with case-specific sequences and washouts.

Intervention

Sequences of hydrogen-rich saline infusion, 3% H₂ inhalation and hydrogen-rich water.

Hydrogen form

Infused H₂-rich saline, inhaled H₂ gas and H₂-rich drinking water.

H₂ specification

Saline 1 ppm, 500 mL over 40 minutes; inhalation 3% for one hour; water 5–7 ppm, 500 mL/day.

H₂ flow

Inhalation delivery described as 3% H₂ for one hour daily.

O₂ delivered with H₂

No therapeutic oxygen co-intervention was reported.

Comparator

Within-case periods, including one placebo-saline phase; no randomized parallel control.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

DAS28, PASI, pain visual-analogue scores and cytokines.

Reported result

The cases show changes in selected clinical scores and cytokines across modality periods, with variable sequences and concomitant care.

Results-extraction completeness

The full article methods, intervention, outcomes, positive and null findings, funding and conflict statements were checked.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Three selected cases, open treatment periods, varying sequences, co-interventions and product-affiliated support create serious bias.

Applies directly to

These three cases only.

Preliminary appraisal framework

JBI case-report or case-series checklist — preliminary

Preliminary risk-of-bias status

Serious concerns

Appraisal rationale

Selection, period effects, co-interventions, nonrandom sequencing and outcome multiplicity prevent causal inference.

Appraisal domains

Selection and allocation checked · Confounding and co-interventions remain possible · Missing observations checked where reported · Outcome measurement varies by endpoint · Selective reporting cannot be excluded

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 25936373 · DOI: 10.3892/mmr.2015.3707

Publisher access

A free publisher or repository full article was checked.

Extraction basis

Publisher or repository full article and bibliographic record; checked 10 August 2026.

Record revision

2026-08-10